Robertas Badaras

Dr. Robertas Badaras

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
ILIndrė Lapinskienė
Indrė Lapinskienė
GMGabija Mikulevičienė
Gabija Mikulevičienė
GLGabija Laubner
Gabija Laubner
RBRobertas Badaras
Robertas Badaras

27 December 2022 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
RSRobertas Strumila
Robertas Strumila
ALAiste Lengvenyte
Aiste Lengvenyte
LZLinas Zdanavicius
Linas Zdanavicius
RBRobertas Badaras
Robertas Badaras
EDEdgaras Dlugauskas
Edgaras Dlugauskas
LALaima Ambrozaitytė
Laima Ambrozaitytė

18 February 2025 in Acta medica Lituanica
Verified
Journal Article
Open access
SKSofija Saulė Kaubrytė
Sofija Saulė Kaubrytė
SCSigitas Chmieliauskas
Sigitas Chmieliauskas
GSGiedrė Salyklytė
Giedrė Salyklytė
SLSigitas Laima
Sigitas Laima
DVDiana Vasiljevaitė
Diana Vasiljevaitė
RBRobertas Badaras
Robertas Badaras
Background: Nitrate and nitrite toxicity, particularly from sodium nitrite and sodium nitrate ingestion, has become a critical public health issue due to its role in accidental poisoning, foodborne exposure, and intentional self-harm. Sodium nitrite, commonly used in food preservation, is increasingly linked to suicide, with online resources providing accessible information on lethal dosages. This trend underscores an urgent need for regulatory action and preventive strategies. This report details a fatal case of nitrate and nitrite toxicity in a 19-year-old female, presenting a complex toxicological profile involving ethyl alcohol, amphetamines, and additional pharmaceuticals.Materials and methods: A systematic literature search was conducted across PubMed and Google Scholar databases, spanning articles published over a period of the last 10 years, utilizing keywords relevant to the topic under consideration and their combinations. 58 pertinent articles were selected, supplemented by data from the Lithuanian State Forensic Medicine Service, involving a clinical case. Autopsy findings, toxicological analyses, and contextual details were meticulously examined to elucidate the mechanism and circumstances of death.Case presentation: A 19-year-old female was found deceased in her home, alongside a suicide note indicating intent to self-harm through ingestion of sodium nitrate, sodium nitrite, and multiple medications. The autopsy findings included cherry-brown lividity, dark, non-coagulated blood within the heart chambers, and significant multi-organ congestion, consistent with methemoglobinemia and systemic hypoxia. Toxicology results confirmed a blood alcohol concentration of 1.22‰, with trace levels of amphetamine, atropine, and quetiapine, while nitrites detected in the gastric contents confirmed sodium nitrite as a primary toxic agent. The toxic synergy of these substances ultimately led to fatal multi-organ compromise.Conclusions: This case emphasizes the serious risks associated with nitrate and nitrite ingestion, particularly in instances of intentional overdose facilitated by readily accessible online information on lethal dosages. The autopsy findings reveal characteristic signs of methemoglobinemia and systemic hypoxia; however, a thorough forensic assessment must also consider additional factors, including the presence of a suicide note, the scene context, and any substances collected at the location.Lessons: Due to the inherent instability of nitrite in blood, its post-mortem detection is often challenging, thereby complicating toxicological confirmation. The increasing accessibility and misuse of sodium nitrite underscore an urgent need for regulatory oversight, public awareness, and enhanced preventive measures to address the rising incidence of intentional sodium nitrite toxicity, particularly within at-risk populations.

11 October 2019 in Journal of Addiction Medicine
Verified
Journal Article
Closed access
RBRobertas Badaras
Robertas Badaras
TJTomas Jovaisa
Tomas Jovaisa
ILIndre Lapinskiene
Indre Lapinskiene
JIJuozas Ivaskevicius
Juozas Ivaskevicius
Context: To describe the role of opioid antagonist induction in reducing stress response and withdrawal symptoms.Objective: Complexity of naltrexone induction is limiting broader applicability of opioid antagonist-assisted abstinence. The aim of this clinical trial was to assess the stress response to 2 low-dose naltrexone induction protocols under minimal oral sedation.Design: Double-blind randomized controlled trial.Setting: Open setting in-patient unit.Participants: Adults with opioid use disorder, and at least a year-long history of opioid use.Intervention protocol: Patients received either a single 12.5 mg naltrexone oral dose (SI group) or escalating dosage regimen starting from 50 μg up to a cumulative dose of 12.5 mg (ED group).Main outcome measure: Differences in cortisol and adrenocorticotropic hormone (ACTH) concentrations 1 hour after the start of naltrexone induction.Results: In all, 124 patients were enrolled and 68 remained in the trial at the point of randomization—33 in SI and 35 in ED group. Eight patients were excluded from final analysis. Plasma cortisol and ACTH concentrations were significantly higher in SI group; mean difference between groups 313 nmol/L (95% confidence interval [CI] 182–444,P < 0.001) and 36.9 pg/mL (95% CI 12.3–61.4,P = 0.004), respectively. Secondary outcomes: SI patients experienced significant increases in plasma cortisol and ACTH concentrations, and withdrawal scores. In ED group these measures remained at or below baseline throughout the 24-hour period from start of naltrexone induction.Conclusions: Contrary to a single 12.5-mg dose, the escalating naltrexone dosing regimen produced no significant increase in stress response and withdrawal scores during antagonist induction.

27 February 2024 in Acta medica Lituanica
Verified
Journal Article
Open access
ALAgnė Lozovskytė
Agnė Lozovskytė
GSGabija Laubner Sakalauskienė
Gabija Laubner Sakalauskienė
RBRobertas Badaras
Robertas Badaras
Simethicone is an antiflatulent medication exclusively administered orally, thus its systemic effects remain unknown. We present a case of an inadvertent intravenous administration of simethicone to a 4-year-old patient, precipitating respiratory difficulty, cyanosis, and altered mental status. The patient’s condition improved rapidly with appropriate interventions, leading to discharge in a fully recovered state. To date, only one documented instance of intravenous simethicone administration exists in medical literature.

4 December 2014 in Medicinos teorija ir praktika
Verified
Journal Article
Closed access
RBRobertas Badaras
Robertas Badaras
GDGabija Dragelytė
Gabija Dragelytė
IVIndrė Vaitekonytė
Indrė Vaitekonytė
JIJuozas Ivaškevičius
Juozas Ivaškevičius
JŠJūratė Šipylaitė
Jūratė Šipylaitė
Materials and Methods. Published articles on the opioid abuse and methods of opioid detoxification were identified by searching medical databases, using corresponding literature and were also searched manually for applicable papers. The search was limited to articles published from 1985 through 2014. Results. Opioid dependence determine pathophysiologic changes in the dopaminergic pathways of the organism, as well as the alterations in the stress-responsive hypothalamic-pituitary-adrenal axis. The usage of opioid antagonists in the early stages of withdrawal, can lead the effectiveness of opioid detoxification to 100%. Rapid opioid detoxification do not remove all the symptoms of abstinence. Negative aspects, concerning the procedure, while using prevention, can be reduced to the minimum risk. Rapid opioid detoxification, comparing it with Ultrarapid opioid detoxification procedure, diverges as less financial resources and a lower risk containing technique. Conclusions. Use of antagonists may reduce the duration of withdrawal, thus reducing the overall severity of withdrawal and increasing the chances of successful completion. This technique facilitates commencement of naltrexone treatment. Dosing regimens used in clinical trials vary. Subsequent results do not correlate with the methods of detoxification.